Klaus B. Mross
Breisacher Str. 117, Freiburg Im Breisgau
Salem, BW 79106, Germany
Salem, BW 79106, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
Journal: Targeted oncology
Published: October 27, 2020
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
Journal: Targeted oncology
Published: April 22, 2020
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 07, 2017
A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: February 16, 2016
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Journal: International journal of clinical pharmacology and therapeutics
Published: May 08, 2014
Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.
Journal: BMC cancer
Published: October 02, 2013
First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.
Journal: PloS one
Published: July 01, 2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 16, 2013
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.
Journal: British journal of cancer
Published: June 16, 2012
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
Journal: British journal of cancer
Published: May 10, 2012
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 17, 2012
Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.
Journal: Current oncology (Toronto, Ont.)
Published: February 14, 2012
Last Updated: 09/26/2026